William Jl Rieflin - 03 Mar 2022 Form 4 Insider Report for NGM BIOPHARMACEUTICALS INC

Role
Executive Chairman, Director
Signature
/s/ Valerie Pierce, Attorney-in-fact
Issuer symbol
N/A
Transactions as of
03 Mar 2022
Net transactions value
$0
Form type
4
Filing time
04 Mar 2022, 15:11:45 UTC
Previous filing
16 Jun 2021
Next filing
04 Apr 2022
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction NGM Stock Option (Right to Buy) Award $0 +80,000 $0.000000 80,000 03 Mar 2022 Common Stock 80,000 $15.20 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The shares subject to the stock option vest over a four-year period commencing January 1, 2022, with 1/48th of the shares vesting on a monthly basis.